- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01080352
Vitamin C as an Anti-cancer Drug
Evaluation of Cytotoxicity and Genetic Changes of High Dose Vitamin C Infusions in Castration Resistant Metastatic Human Prostate Cancer
Can high dose, intravenous Vitamin C prolong life for patients with metastatic prostate cancer?
Prostate cancer is the most common cancer (excluding skin cancer) in men in Denmark and the Unites States. When metastatic disease is present cure is no longer possible. The main treatment at this stage is castration, either surgical or medical, ending the patients testosterone production and causing a temporary regression in disease activity.
Eventually, the cancer will progress, usually within 2 years from the castration, with a more aggressive course and a survival of 2-3 years.
The current treatment option for the patients, who have undergone castration and have disease progression, is chemotherapy with only limited gains in quality of life and survival.
This clinical study is a phase 2 study to evaluate the effects of high dose intravenous vitamin c in subjects with early castration resistant prostate cancer.
Primary endpoint:
- Prostate specific antigen (PSA) changes after 12 to 20 weekly vitamin c infusions
Secondary endpoints:
- Bone metastases changes after 12 to 20 weekly vitamin c infusions
- Changes in bone specific alkaline phosphates, oxidative DNA-damage, PINP, NTX after 12 to 20 weekly vitamin c infusions
- RNA-expression changes in prostatic tumor tissue after 12 to 20 weekly vitamin c infusions
- RNA-expression changes in lymphocytes after 12 to 20 weekly vitamin c infusions
Tertiary endpoints:
- Pharmacokinetics of vitamin c in the elderly cancer patients
Methods and material:
- 80 subjects are included (efficacy evaluation when 20 subjects have been evaluated for extension arm)
- Each subject receives a weekly infusion of 60 grams vitamin c (in the form of ascorbate) for 12 to 20 weeks
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Vitamin C for palliative treatment:
Intravenous vitamin C has been used since the 1970's for terminally ill cancer patients claiming big increases in survival time. The efficacy of the drug is questioned and no randomized, controlled trial of Vitamin C's efficacy on cancer patients survival has been made.
Recent results from in vitro and xenograft studies in mice has shown some promise for vitamin c as a cytotoxic agent against cancer cells.
The following parameters are recorded for baseline:
- Biomarkers (PSA, bALP, NTX, PINP)
- Routine blood work (hgb, creatinine, p-vitamin c etc.)
- Radio nucleotide bone scintigraphy
- Prostate biopsies for later microarray (Affymetrix ST1.0)
- Urine samples 8-oxo-guanine(for oxidative DNA-damage measurements)
These parameters are repeated after treatment, usually after 12 to 26 weeks after the first vitamin c infusion.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
DK
-
Herlev, DK, Denmark, 2730
- Departmen of Urology, Copenhagen University Hospital at Herlev
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Castration resistant metastatic prostate cancer (bony or visceral metastases)
- Gleason sum > 6
- PSA > 10 ng/ml
- ECOG < 3
- Prior orchidectomy or LHRH antagonist/agonist treatment
- Must give informed content
Exclusion Criteria:
- Synchronous active cancer (skin cancer excluded)
- Prior chemotherapy
- History of oxalate renal stones
- Glucose-6-phosphate dehydrogenase deficiency
- Impaired renal function (creatinine > 200micromoles/L
- Haemochromatosis
- Cardiac disease (NYHA > 2, CSS > 2, recent AMI (less than 6 months)
- Recent major surgery (less than 4 weeks before inclusion and more than 2 days of admittance time)
- Prior intended curative treatment of prostate cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vitamin C treatment
Each subjects receive 12 weeks of 1 weekly treatment with intravenous vitamin c. 5grams are given at week 1, 30 grams at week 2 and 60 grams at week 3-12. If eligibility criteria are met the subject may continue with 1 weekly vitamin c treatment of 60 grams at week 13-20. |
60grams of ascorbate given intravenous infusion in 1000ml sterile water.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PSA changes after 12-20 weeks of treatment
Time Frame: 12, 20 and 26 weeks
|
12, 20 and 26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bone metastases changes
Time Frame: 12, 26 and 52 weeks
|
12, 26 and 52 weeks
|
bALP changes
Time Frame: 12, 20, 26 and 52 weeks
|
12, 20, 26 and 52 weeks
|
NTX changes
Time Frame: 12, 20, 26 and 52 weeks
|
12, 20, 26 and 52 weeks
|
PINP changes
Time Frame: 12, 20, 26 and 52 weeks
|
12, 20, 26 and 52 weeks
|
8-oxo-guanine changes
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kari J Mikines, MD, DsMC, Copenhagen University Hospital at Herlev
Publications and helpful links
General Publications
- Nielsen TK, Hojgaard M, Andersen JT, Jorgensen NR, Zerahn B, Kristensen B, Henriksen T, Lykkesfeldt J, Mikines KJ, Poulsen HE. Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial. Transl Androl Urol. 2017 Jun;6(3):517-528. doi: 10.21037/tau.2017.04.42.
- Nielsen TK, Hojgaard M, Andersen JT, Poulsen HE, Lykkesfeldt J, Mikines KJ. Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluation. Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):343-8. doi: 10.1111/bcpt.12323. Epub 2014 Oct 7.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008-008692-33
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
Clinical Trials on Ascorbic Acid (Vitamin C)
-
In-Young Choi, Ph.D.CompletedType 2 Diabetes | Oxidative StressUnited States
-
DongGuk UniversityKorean Association For Vitamin ResearchCompleted
-
Health Innovations, Frontier Research InstituteTerminatedHepatitis CUnited States
-
University of Colorado, DenverNational Institutes of Health (NIH); American Diabetes AssociationCompletedType 2 DiabetesUnited States
-
Situs Cancer Research CenterSuspendedSarcoma | Adenocarcinoma | Carcinoma | Multiple Myeloma | Desmoplastic Small Round Cell TumorUnited States
-
University of Alabama at BirminghamTerminatedNosocomial Pneumonia | CoagulopathyUnited States
-
Oregon Health and Science UniversityNational Heart, Lung, and Blood Institute (NHLBI); Office of Dietary Supplements...CompletedSecond Hand Smoke | Pulmonary Function; Newborn, Abnormal | Infant Wheeze | In-utero NicotineUnited States
-
Ain Shams UniversityCompleted
-
University of North Carolina, Chapel HillNational Institute of Nursing Research (NINR); Sigma Theta Tau International...Completed
-
University of AberdeenUniversity of OtagoNot yet recruiting